|
1. |
The necessity of a second prostate biopsy cannot be predicted by PSA or PSA derivatives (density or free:total ratio) in men with prior negative prostatic biopsies |
|
Current Opinion in Urology,
Volume 9,
Issue 5,
1999,
Page 371-375
Omar Hayek,
Cyrus Noble,
Alexander de la Taille,
Emilia Bagiella,
Mitchell Benson,
Preview
|
|
摘要:
Serum prostate specific antigen, prostate specific antigen density and free:total prostate specific antigen are known to be useful for determining the risk of prostate cancer in patients undergoing prostate cancer screening. The patient with a positive biopsy presents no future prostate specific antigen dilemma. Those with negative biopsies often go on to numerous repeat biopsies. Our goal was to establish criteria that could be used to identify patients who will require repeat prostate biopsies (possibly false negative initial biopsy), while not exposing the low risk population (probable true negative initial biopsy) to additional invasive procedures. Between March 1991 and March 1998, 148 patients who had a biopsy for an elevated prostate specific antigen value (4.1-10.0) or an altered digital rectal examination, had no cancer found in the specimen. From these, 51 (34.4%) had repeated biopsies, while the others persisted on close follow-up. We examined their serum prostate specific antigen, prostate specific antigen density and free:total prostate specific antigen value, as well as their age and histology results of the initial and repeat biopsy, to determine if any predictor of the need for a repeat biopsy could be identified. Eight (15.7%) from 51 men who had repeat biopsy had prostate cancer detected. Forty three (84.3%) patients persisted with a negative biopsy, despite filling the criteria for re-biopsy. Multivariate analysis failed to identify any significant predictors of prostate cancer in the repeat biopsy group. Despite initial success, the prostate specific antigen derivatives and free:total prostate specific antigen have not safely limited the number of biopsies performed for an abnormal prostate specific antigen (4.1-10.0). Neither prostate specific antigen density nor free:total prostate specific antigen predicted the need for repeat biopsy in this specific group. The results of this ongoing study demonstrate that to date, prostate specific antigen and prostate specific antigen derivatives can not be utilized to determine which patients will be at high risk for requiring repeat prostate biopsy. All patients must be closely monitored for evidence of a change in status from benign to malignant disease, and new markers for this purpose are urgently needed.
ISSN:0963-0643
出版商:OVID
年代:1999
数据来源: OVID
|
2. |
Renal cell carcinoma: should radical nephrectomy be performed in the presence of metastatic disease? |
|
Current Opinion in Urology,
Volume 9,
Issue 5,
1999,
Page 377-381
Ihor Sawczuk,
Jason Pollard,
Preview
|
|
摘要:
Metastatic renal cell carcinoma is associated with an unfavorable prognosis and the treatment options are limited. Adjunctive radical nephrectomy, performed either before or after the administration of systemic immunotherapy, has been proposed as a means of improving outcome. The role of nephrectomy for patients with metastatic disease remains controversial. This article reviews the role of nephrectomy in metastatic renal cell carcinoma and the optimal timing for surgery relative to immunotherapy.
ISSN:0963-0643
出版商:OVID
年代:1999
数据来源: OVID
|
3. |
Is open surgery for partial nephrectomy an obsolete surgical procedure? |
|
Current Opinion in Urology,
Volume 9,
Issue 5,
1999,
Page 383-389
Clément-Claude Abbou,
András Hoznek,
Laurent Salomon,
Mohamed Slama,
Dominique Chopin,
Preview
|
|
摘要:
During the past few years, the indications for laparoscopic surgery in urology have extended from simple ablative procedures towards more complex reconstructive and organ-preserving interventions. Among them, transperitoneal and extraperitoneal laparoscopic partial nephrectomy have been successfully performed for both benign and malignant lesions. However, this approach raises specific problems because in contrast to other laparoscopic procedures the techniques and tools used during open surgery can not be simply transposed to laparoscopy. The absence of surface hypothermia, the lack of manual palpation, difficulties of vascular control and reconstruction of the collecting system necessitate new solutions readily adaptable to laparoscopic surgery. However, the available series comprise only a few cases, and there are differences in techniques and instrumentation in almost every operation. In these circumstances, it is too early to consider this new approach as reproducible and ready to be used elsewhere than in specialized centres. Although the feasibility and good results of partial nephrectomy for benign conditions and small exophitic tumours is now well documented, the development of new surgical tools and standardization of methodology are required for more complex cases within the scope of well conceived prospective studies.
ISSN:0963-0643
出版商:OVID
年代:1999
数据来源: OVID
|
4. |
Monoclonal antibodies: will they become an integral part of the evaluation and treatment of prostate cancer - focus on prostate-specific membrane antigen? |
|
Current Opinion in Urology,
Volume 9,
Issue 5,
1999,
Page 391-395
Sam Chang,
Neil Bander,
Warren Heston,
Preview
|
|
摘要:
Over the past two decades, monoclonal antibody technology has had an increasing impact on clinical diagnostic and therapeutic options, and this is true in the realm of managing prostate cancer. Several targets such as prostate-specific antigen and prostatic acid phosphatase as well as, more recently, angiogenic antigens such as vascular endothelial growth factor have been examined for therapy. Prostate-specific membrane antigen, a type II integral membrane glycoprotein initially characterized by the monoclonal antibody 7E11, has shown promise. Recent evidence suggests that prostate-specific membrane antigen is also expressed in tumor-associated neovasculature of a wide variety of malignant neoplasms. With its expression in prostate secretory-acinar epithelium and the prostate and in the neovasculature associated with tumors, prostate-specific membrane antigen represents an excellent antigenic target for monoclonal antibody diagnostic and therapeutic options. As research continues, the role of monoclonal antibody imaging and therapy will become increasingly important in the management of prostate cancer.
ISSN:0963-0643
出版商:OVID
年代:1999
数据来源: OVID
|
5. |
Oncology: bladder and testis |
|
Current Opinion in Urology,
Volume 9,
Issue 5,
1999,
Page 397-399
Frans Debruyne,
Preview
|
|
ISSN:0963-0643
出版商:OVID
年代:1999
数据来源: OVID
|
6. |
Markers for recurrence of superficial bladder cancer: what is valid? |
|
Current Opinion in Urology,
Volume 9,
Issue 5,
1999,
Page 401-406
Henk van der Poel,
Preview
|
|
摘要:
The management of superficial bladder cancer is characterized by early recognition of recurrences and the prevention of progression. Several clinical markers are used to divide patients into risk groups determining treatment and follow-up schemes. Although only a small fraction of patients will progress to invasive disease, survival of these patients is largely dictated by their bladder cancer. Whether early aggressive treatment of ‘high-risk’ superficial bladder cancer improves survival is not the issue of this article. Here we discuss the markers available for predicting tumour recurrence and progression. Clinical markers remain the most practical in decision-making and can identify high-risk patients. Molecular markers may be useful, but as yet insufficient evidence exists on their efficacy for daily use.
ISSN:0963-0643
出版商:OVID
年代:1999
数据来源: OVID
|
7. |
Recent perspectives in topical therapy in superficial bladder cancer |
|
Current Opinion in Urology,
Volume 9,
Issue 5,
1999,
Page 407-411
Andreas Böhle,
Christoph Durek,
Preview
|
|
摘要:
With regard to side-effects in intravesical bacillus Calmette-Guérin instillation therapy and the limited efficacy of intravesical chemotherapy, there is still a need for improvement of these standard therapies. Recently, technical adjuvant means or the modification of cytostatic drugs have been undertaken to improve the efficacy of intravesical chemotherapy. Prognostic indicators of the response to bacillus Calmette-Guérin immunotherapy have been identified, but indicators of side-effects are needed in order to improve the benefit-to-risk ratio of bacillus Calmette-Guérin instillation therapy. Many innovative treatment options, however, still require a definition of their clinical value.
ISSN:0963-0643
出版商:OVID
年代:1999
数据来源: OVID
|
8. |
Surgery for invasive bladder tumors: technique and outcome |
|
Current Opinion in Urology,
Volume 9,
Issue 5,
1999,
Page 413-418
Peter Clark,
Eric Klein,
Preview
|
|
摘要:
The operative management of invasive transitional cell carcinoma has advanced significantly in the past year, particularly with respect to continent urinary diversion. The long term safety and efficacy of this form of urinary reconstruction is being established in terms of both operative and metabolic complications. The availability of continent diversion can decrease the interval to cystectomy and therefore may impact positively on survival. It has also been shown that continent diversion can safely be offered to patients at high risk for local recurrence. The importance of urethral sensory threshold on postoperative continence is being established. These findings and others continue to enhance the survival and quality of life of patients undergoing cystectomy for invasive bladder cancer.
ISSN:0963-0643
出版商:OVID
年代:1999
数据来源: OVID
|
9. |
Neo-adjuvant and adjuvant treatment of locally invasive bladder cancer |
|
Current Opinion in Urology,
Volume 9,
Issue 5,
1999,
Page 419-424
Daniela Schultz-Lampel,
Alexander Lampel,
Preview
|
|
摘要:
Since Sternberget al. in 1985 first published preliminary results of polychemotherapy in patients with metastatic bladder cancer, it became apparent that transitional carcinoma of the bladder is highly responsive to chemotherapy. Response rates up to 70% with combination therapy regimens like methotrexate, vinblastine, doxorubicin or adriamycin and cisplatin promised that transitional carcinoma might be able to cure even in advanced stages. Chemotherapy has either been applied prior to the local treatment (such as radical cystectomy or radiotherapy) in a neo-adjuvant regimen, or after local therapy in an adjuvant regimen. Although a large number of studies have been published in the past 20 years, the role of the different chemotherapeutic approaches has not been clearly defined. Therefore, neither neo-adjuvant nor adjuvant chemotherapy can be recommended as ‘gold standard’ treatment for advanced bladder cancer.
ISSN:0963-0643
出版商:OVID
年代:1999
数据来源: OVID
|
10. |
Health-related quality of life in patients treated for testicular cancer |
|
Current Opinion in Urology,
Volume 9,
Issue 5,
1999,
Page 425-429
Sophie Fosså,
Alv Dahl,
Carl Haaland,
Preview
|
|
摘要:
Cross-sectional studies have shown that long-term health-related quality of life is satisfactory in the majority of testicular cancer patients, in spite of slight to moderate physical morbidity (sexual dysfunction, infertility) in at least a third of them. Modern risk-adapted treatment of testicular cancer patients will hopefully decrease the long-term sequelae furthermore. Prospective studies are needed to identify those patients at increased risk of developing major physical or psychosocial problems, and to study the role of medical and psychological intervention at an early phase of the clinical course in these patients. The long-term investigation and follow-up of testicular cancer survivors provide useful information on survivorship problems in cured cancer patients in general.
ISSN:0963-0643
出版商:OVID
年代:1999
数据来源: OVID
|
|